Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-11-02

FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)

View source ↗

Summary

The FDA approved a supplemental application for rivastigmine by Sandoz Inc, updating the approval status of this product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rivastigmine (Rivastigmine)

Snippet

SUPPL AP for RIVASTIGMINE (RIVASTIGMINE)